4 Papers
1 Citations
Yan Cheng is an academic researcher from Tianjin Medical University General Hospital. The author has contributed to research in topics: Medicine & Ropinirole. The author has an hindex of 3, co-authored 4 publications. Previous affiliations of Yan Cheng include Tianjin Medical University.
Chat about Author
Papers
The recommendations of Chinese Parkinson’s disease and movement disorder society consensus on therapeutic management of Parkinson’s disease
Sheng-Di Chen,Piu Chan,Shenggang Sun,Haibo Chen,Baorong Zhang,Weidong Le,Chun-Feng Liu,Guoguang Peng,Beisha Tang,Li-Juan Wang,Yan Cheng,Ming Shao,Zhen-Guo Liu,Zhenfu Wang,Xiaochun Chen,Mingwei Wang,Xinhua Wan,Huifang Shang,Yi-Ming Liu,Pingyi Xu,Jian Wang,Tao Feng,Xianwen Chen,Xingyue Hu,An-Mu Xie,Qin Xiao +25 more
TL;DR: A set of treatment recommendations has been developed to assist physicians to improve and optimize clinical outcomes for patients with PD in China, including physical activity and disease-modifying medication, which should be initiated at the early-stage of the disease.
The efficacy and safety of ropinirole prolonged release tablets as adjunctive therapy in Chinese subjects with advanced Parkinson's disease: A multicenter, double-blind, randomized, placebo-controlled study
Zhen-Xin Zhang,Jian Wang,Xiaoying Zhang,Sheng-Di Chen,Zhenfu Wang,Baorong Zhang,Chun-Feng Liu,Qiumin Qu,Yan Cheng,Jie Li,Haijun Cao,Meng Cai,Rongxuan Zhu +12 more
TL;DR: This study demonstrated for the first time in Chinese subjects that ropinirole PR improved Parkinson's disease symptoms, permitting a reduction in L-dopa dose.
29
An open-label extension study to evaluate the safety of ropinirole prolonged release in Chinese patients with advanced Parkinson's disease.
Zhen-Xin Zhang,Jian Wang,Xiaoying Zhang,Sheng-Di Chen,Zhenfu Wang,Baorong Zhang,Chun-Feng Liu,Qiumin Qu,Yan Cheng,Rongxuan Zhu,Jie Li,Jingqiu Hu,Meng Cai +12 more
TL;DR: Results support the long-term use of ropinirole PR as an adjunctive to levodopa in Chinese patients with advanced Parkinson’s disease and were consistent with the preceding DB study and also with the established safety profile for ro pinirole.
8
Corrigendum to “The efficacy and safety of ropinirole prolonged release tablets as adjunctive therapy in Chinese subjects with advanced Parkinson’s disease: A multicenter, double-blind, randomized, placebo-controlled study” [Parkinsonism and Related Disorders 19 (2013) 1022–1026]
Zhen-Xin Zhang,Jian Wang,Xiaoying Zhang,Sheng-Di Chen,Zhenfu Wang,Baorong Zhang,Chun-Feng Liu,Qiumin Qu,Yan Cheng,Jie Li,Haijun Cao,Meng Cai,Rongxuan Zhu +12 more
TL;DR: Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, No. 1 Shuaifuyuan, Wangfujing, Beijing 100730.
1